Tarceva
Tarceva fails to win NICE backing
June 30, 2011Sales and Marketing NICE, Tarceva
NICE has decided not to recommend Roche’s Tarceva because of uncertainty over how long the lung cancer drug can extend …
Tarceva impresses again as it seeks to extend its EU licence
June 3, 2011NSCLC, Roche, Tarceva
Roche and its partner OSI Pharmaceuticals have released another series of positive results for its lung cancer drug Tarceva as …
Merck re-submits Erbitux to the EMA for lung cancer
March 30, 2011Sales and Marketing EGFR, Erbitux, Iressa, Merck KGaA, NSCLC, Tarceva, lung cancer drugs, non-small cell lung cancer
Merck KGaA has re-submitted Erbitux’s lung cancer licence extension to the EMA after its first application to the regulator was …
No magic bullet, but a growing arsenal against lung cancer
February 23, 2011Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer
A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …
Tarceva set for first line treatment
January 31, 2011Sales and Marketing Iressa, NSCLC, Roche, Tarceva
Roche’s lung cancer treatment Tarceva has been shown to help patients as a first line treatment. An independent data monitoring …
Roche set to challenge NICE Tarceva decision
November 25, 2010Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer
NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …
Roche to develop diagnostic tools for Tarceva
November 23, 2010Sales and Marketing Genzyme, NSCLC, Roche, Tarceva, diagnostic
Roche has obtained a worldwide sub-license from Genzyme to develop a diagnostic kit for the detection of specific mutations for …
Sutent disappoints in lung cancer
August 24, 2010Research and Development, Sales and Marketing NSCLC, Pfizer, Sutent, Tarceva
Pfizer’s Sutent has failed to improve overall survival in lung cancer patients when combined with Roche’s Tarceva. Pfizer’s SUN 1087 …
NICE rejects Tarceva maintenance treatment
June 17, 2010Sales and Marketing NICE, NSCLC, Roche, Tarceva, lung cancer
Roche’s Tarceva should not be used in lung cancer patients who have already been treated and whose disease remains stable, …
Tarceva gets nod for maintenance treatment
March 22, 2010Sales and Marketing Tarceva, lung cancer
Tarceva looks set to gain approval in Europe to treat patients with non-small cell lung cancer whose disease remains stable …
NICE judges Tarceva too expensive for NHS
March 9, 2007Sales and Marketing Tarceva, lung cancer
Roche's cancer drug Tarceva has been rejected by NICE for use against the most common form of lung cancer.The watchdog …
NICE to say no to Tarceva
November 17, 2006Sales and Marketing NICE, Tarceva
Roche's new lung cancer treatment Tarceva looks set to be refused recommendation from NICE.Tarceva (erlotinib) is the first next-generation treatment …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
